Questions About Cancer? 1-800-4-CANCER
NCI Cancer Center News

Adding bavituximab to second-line chemotherapy doubles response rate

  • Posted: September 7, 2012

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to University of Texas Southwestern Medical Center research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. UT Southwestern is home to the Harold C. Simmons Cancer Center.

Click here to read full press release.

###

NCI cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.